Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron added to risperidone for autism spectrum disorder
IRCT20200317046801N2Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Risperidone + ondansetron with Risperidone + placebo (2 arms). Primary endpoint: Symptoms of autism spectrum disorder. Started Sep 2020; status: completed.
02
Drugs
ondansetron
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20200317046801N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200317046801N2.